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Bone metastasis occurs in the majority of late-stage tumors with poor prognosis. It is mainly classiﬁed as
osteoblastic metastasis and osteolytic metastasis. The pathogenesis of osteolytic metastasis is a “vicious
cycle” between tumor cells and bone cells (primarily the osteoclasts), which is mediated by secretory
factors. The P62 adapter protein is a versatile multitasker between tumor cells and bone cells. The
overexpression of P62 has been detected among a variety of tumors, playing positive roles in both tu-
morigenesis and metastasis. Moreover, P62 is an important modulator of the osteoclastogenesis pathway.
Therefore, the ability of P62 to modulate tumors and osteoclasts suggests that it may be a feasible on-
cotarget for bone metastasis, especially for osteolytic metastasis. Recent research has shown that a P62
DNA vaccine triggered effective anti-tumor, anti-metastatic and anti-osteoporotic activities. Growing
lines of evidence point to P62 as an emerging oncotarget for osteolytic metastasis. In this review, we
outline the different roles of P62 in tumor cells and osteoclasts, focusing on the P62-related signaling
pathway in key steps of osteolytic metastasis, including tumorigenesis, metastasis and osteoclastogen-
esis. Finally, we discuss the newest observations on P62 as an oncotarget for osteolytic metastasis
treatment.
& 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
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Up to 90% of patients with multiple myeloma, and 60–75%
patients with prostate cancer and breast cancer develop bone
metastasis at the later stages of their diseases [1]. Metastaticicle under the CC BY-NC-ND license
Fig. 1. P62 structure, interaction domains and function. P62 has six main functional domains: PB1, ZZ, TB, LIR, KIR and UBA. The PB1 domain binds PKC. The ZZ zinc-ﬁnger
domain binds receptor interacting protein (RIP).The TRAF6 binding (TB) domain binds TRAF6. Three domains link p62 to NF-κB activation, which is relevant in RANK-induced
osteoclastogenesis, as well as in Ras-induced tumorigenesis. PB1 domain also self- and hetero- oligomerizes with NBR1, which might restrain autophagy through mTOR
activation. The LIR domain interacts with autophagosome protein LC3, serving to control p62 levels in autophagy. The KIR domain binds Keap1, which might be important for
the regulation of Nrf2 and the control of ROS levels in oxidative stress. The UBA domain regulates the interaction of p62 with poly-ubiquitylated proteins targeted for
degradation by the proteasome or autophagy. In addition, p62 has two PEST sequences that are targets for post-translation modiﬁcations and degradation. P62 also contains
two NLS sequences and a NES sequence which allow p62 shuttling into and out of nucleus. NLS2 domain phosphorylated by CDK1 that regulates cell cycle.
J. Zhang et al. / Journal of Bone Oncology 5 (2016) 30–37 31lesions in bone are signiﬁcantly associated with bone pain,
hypercalcemia or hypocalcemia, pathological fracture and spinal
cord compression, which mostly correlated to low 5-years survi-
val-rate less than 30% [2]. Relative to osteoblastic metastasis,
osteolytic metastasis is more difﬁcult to treat, making the need
to study its pathogenesis. Recent advances in the understanding
of osteolytic metastasis revealed that it is associated with char-
acteristic modulations of the bone microenvironment and cross-
talk between the tumor cells and bone cells (primarily the osteo-
clasts). Tumor cells condition the “metastatic niche” through the
secretion of soluble factors that stimulate bone resorption by the
osteoclasts. Osteoclastic bone resorption results in the release and
activation of growth factors in the bone microenvironment that
further stimulate tumor growth, leading to a “vicious cycle” [3]. It
is involved with numerous signaling factors, but the crucial mo-
lecules are still uncertain [1].
Since its initial discovery as an atypical protein kinase C (PKC)-
interacting protein, P62 (also known as sequestosome-1, SQSTM-1
or A170) has emerged as a crucial molecule in the regulation of cell
growth, survival and proliferation [4]. The human P62 protein has
440 amino acid residues and contains different types of protein–
protein interaction domains. The multi-functional domains of the
P62 adapter protein are consistent with its role as a versatile
multitasker in signal transduction in tumors [5], (Fig. 1). P62
accumulation promotes tumorigenesis [6]. It is found to be either
not expressed or found at low levels of expression in normal
tissues, but is over-expressed among various types of tumors and,
for the most part, is correlated with tumor migration, invasion orFig. 2. Receptor P62 in aggrephagy model. The ligand (ubiquitin) is the recognition com
interaction between the receptor and adapter is vital for cargo recruitment to the phap
FYVE protein (ALFY) interacts both with the receptor P62 and with components of the co
around the cargo to be degraded.metastasis [7–24]. Thus, the P62 gene is generally acknowledged
to be an oncogene. In addition, many studies on Paget's disease of
bone (PDB), which is a skeletal disorder characterized by osteolytic
lesions and overactive osteoclasts, have identiﬁed P62 as an
important modulator of the osteoclastogenesis pathway [25–27].
The dysregulated expression of the P62 protein promotes osteo-
clastogenesis, bone resorption and osteolytic lesions. Therefore,
P62 has long been thought of as a promising molecular target in
PDB and other bone metabolic diseases [28].
Many in vitro and in vivo studies employing knockdown have
shown that P62 can inhibit tumor formation, proliferation and/or
progression [29–31]. Recent research on intramuscularly or in-
travenously administered P62 DNA vaccines showed that they
induced anti-P62 antibodies and exhibited strong anti-tumor and
anti-metastatic activities in transplantable mouse tumors [32] and
canine spontaneous mammary neoplasm models [33]. The latest
research reported the unexpected ﬁnding that intramuscular
delivery of P62 DNA vaccines exerts a powerful anti-osteoporotic
activity in a mouse model of inﬂammatory bone loss [34]. These
studies promoted P62 as an oncotarget for bone metastasis,
especially for osteolytic metastasis.
In this review, we outline the different role of P62 in tumor cell
and osteoclast, focusing on the P62-related signal pathway in key
steps of osteolytic metastasis, including tumorigenesis, metastasis
and osteoclastogensis. Finally, we discuss the newest observations
about P62 as an oncotarget for osteolytic metastasis treatment.ponent on the cargo (aggregate-prone proteins) that binds a receptor (P62). The
ophore assembly site, where an autophagosome forms. Adapter autophagy-linked
re Atg5–Atg12 machinery to facilitate formation of the autophagosomal membrane
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2.1. P62 accumulation promotes tumorigenesis
P62 is over-expressed among almost all differently primary
tumors, including prostate [7–9], breast [10–13], lung [14], kidney
[15], head and neck [16], esophageal [17], gastric [18], liver [19],
colon [20], and ovarian [21] tumors, and myelomas [22], melano-
mas [23], and glioblastomas [24]. This implies that P62 may play
an extensive role in tumorigenesis. Using immunohistochemical
staining and an enzyme-linked immunosorbent assay, P62 over-
expression was shown to be localized to the tumor cell cytoplasm
and nucleus [12,22,24], which suggested that P62 may shuttle in
transcription and translation signaling of tumor cells.
First, P62 promotes tumorigenesis through the autophagy
pathway. Autophagy is a homeostatic process that occurs in all
eukaryotic cells and involves the sequestration of cytoplasmic
components (proteins and organelles) in double-membraned
autophagosomes [35]. P62 has been shown to be both an auto-
phagy substrate and an autophagy adapter protein that acts as a
link between ubiquitination and autophagy. Defects in autophagy
promote a failure of protein and organelle quality control in cells,
which leads to P62 accumulation, resulting in perturbation of gene
expression, increased genome damage and tumorigenesis [6].
Meanwhile, autophagy can be categorized as either nonselective
or selective. Nonselective autophagy randomly engulfs a portion of
the cytoplasm into autophagosomes and then delivers them to
lysosomes for degradation. Selective autophagy, however, speciﬁ-
cally recognizes and degrades a particular cargo, either a protein
complex, an organelle, or an invading microbe [36]. It is likely that
the failure to properly remove the damaged cargo (i.e., the ag-
gregation-prone proteins) by selective autophagy (aggrephagy)
contributes to tumors [37]. Recent studies have implied that P62
plays a receptor role in aggrephagy. The phosphorylation of P62 at
Ser403 regulates the selective autophagic clearance of the ubi-
quitinated aggregated proteins [38,39]. The mechanism of function
in the aggrephagy of P62 can be described as a cargo–ligand–re-
ceptor–adapter model (Fig. 2). In short, as a receptor protein in the
aggrephagy pathway, P62 plays a positive role in tumorigenesis.
Secondly, P62 is required for Ras-induced tumorigenesis. The
Ras proto-oncogene has been found to be mutated in at least 25%
of human tumors and is a potent activator of NF-κB, which is
important for cell survival and tumor transformation [40]. P62 is
an important NF-κB mediator of Ras-induced tumorigenesis
[41,42]. In a model of Ras-induced lung adenocarcinoma, in vitro
and in vivo, P62 was induced by Ras to trigger IκB kinase (IKK)
through the polyubiquitination of tumor necrosis factor (TNF)
receptor-associated factor 6 (TRAF6). Then, activation of NF-κB
increased inﬂammation and tumorigenesis. Deﬁciency of P62 also
accounted for enhanced cell death and reduced the tumorigenicity
of Ras [41]. Another recent study found that P62 plays an im-
portant role in the development of pancreatic ductal adenocarci-
nomas through a feedforward loop, whereby Ras activates NF-κB;
NF-κB then transcriptionally induces P62 [42]. Therefore, P62 is a
positive mediator in Ras-induced tumorigenesis by activation of
NF-κB.
Finally, P62 is a new mediator of oxidative stress signaling
in tumorigenesis. Oxidative stress is common in tumor micro-
environment. Oxidative stress produces additional reactive oxygen
species (ROS), which increase tumorigenesis through the induc-
tion of genome instability [43]. As an emerging regulator at
the interface of oxidative stress signaling and tumorigenesis, P62
was shown to interact with Kelch-like ECH-associated protein 1
(KEAP1) at the transcription factor NF-E2-related factor 2 (NRF2)
binding site, thereby competing with KEAP1 binding and thus
promoting NRF2 release from KEAP1 [44]. Finally NRF2 activationinduced many antioxidant gene expressions, which promoted cell
survival and tumorigenesis [45]. Additionally, animal models with
genetically-impaired autophagy initiation also reveal P62 accu-
mulation, prolonged NRF2 activation, which leaded to tumor cell
survival and tumorigenesis [46].
2.2. P62 plays different roles in tumor metastasis under different
autophagy conditions
Recently, we also reviewed complex correlation between au-
tophagy and cancer metastasis [47]. Autophagy may serve as a
double-edged sword depending on the contextual demands placed
on tumor cells throughout the metastatic process [48]. Latest re-
search implied autophagy may play a role in cancer metastasis via
promoting metastatic colonization [49]. P53 status may determine
the role of autophagy in tumor development [50]. When p53 is
functional, autophagy is required for tumor progression, but that
autophagy might function as part of the tumor-suppression
machinery when the function of p53 is lost [51].
P62 is over-expressed in primary tumor tissues, but there is little
research on P62 expression in metastatic tumor tissues. The results
appear to be contradictory. Kim evaluated autophagy activity in
pulmonary metastasis of colorectal tumors and compared recurrence
and non-recurrence groups. The results showed enhanced autophagy
activity and decreased P62 expression in the recurrence group [52].
Another study showed there was no difference in P62 expression
according to histologic subtypes in metastatic tumor tissues of un-
known primary tumors [53]. However, in a mouse colorectal lung
metastatic model, P62 levels were increased because autophagy ac-
tivity was inhibited [54]. Generally speaking, in established tumors,
autophagic responses constitute a means to cope with intracellular
and environmental stress, thus favoring tumor metastasis [47,55]. As
a substrate protein of autophagy, overactive autophagy leads to P62
degradation. Therefore, it seems that P62 expression is negatively
correlated with tumor metastasis.
However, in autophagy deﬁcient cells, P62 plays different roles
in tumor progression or metastasis. Qiang demonstrated that, in
autophagy deﬁciency cells, P62 accumulation promotes cell pro-
liferation and migration through P62-dependent stabilization of
the oncogenic transcription factor Twist1, and in a mice model,
P62 up-regulation promoted tumor growth and metastasis [56].
Another study showed that interrupting P62 with TRB3 causes P62
accumulation, which produces potent anti-tumor efﬁcacies against
tumor growth and metastasis [57]. Interestingly, recent research
demonstrated that P62 and autophagy synergize to promote
tumor growth and metastasis. In autophagy-deﬁcient established
murine tumors, increased P62 potentiated NF-κB signaling and
the elaboration of pro-tumorigenic inﬂammatory cytokines to
promote tumor growth and metastasis [58]. Therefore, “doubling
down” on the P62 and autophagy pathway reveals an unexpected
synergism [59]. It could be more effective than targeting either
pathway alone to suppress tumor growth and metastasis. We then
speculated P62 might play a dual role in tumor metastasis: under
active autophagy status, as an autophagy receptor and substrate,
P62 degradation promotes tumor metastasis, but under deﬁcient
autophagy status, P62 accumulation potentiates NF-κB signaling to
promote tumor metastasis.3. The role of P62 in osteoclastogenesis
3.1. P62 plays a positive role in osteoclastogenesis through the NF-κB
activation pathway
Bone is continuously renewed through the dynamic balance
between bone resorption and bone formation. Osteoclasts play a
Fig. 3. Osteoclastogenesis induced by adapter P62 in NF-κB activation pathway. RANKL activates both canonical and noncanonical pathways of NF-κB in osteoclastic like cells. In
the canonical pathway, RANKL and IL-1 binding to RANK leads quickly TRAF-6 binding to TB domain of P62. Deubiquitinating enzyme CYLD targets TRAF6 via its interaction
with the UBA domain of P62. P62 activated aPKC, which induce activation of IKK and IκBα. IκBα consequently undergoes rapid degradation by proteasome, resulting in release
of p65 and p50 and their translocation to nuclei where they prevent apoptosis of osteoclast precursors, thus allowing them to continue differentiating. In the noncanonical
pathway, RANKL binding to RANK interacts with TRAF3, activation of the NF-kB inducing kinase (NIK) and IKKa, lead to the phosphorylation of p100 and the processing of
p100–p52.
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and the interactions of tumor cells with osteoclasts disturb this
balance and lead to osteolytic metastasis. The receptor activator of
the nuclear factor-κB ligand (RANKL) is the key cytokine that in-
duces osteoclastogenesis. After secretion by osteoblast, RANKL
binds to its membrane-bound RANK receptor and results in sig-
naling cascades that ultimately activate transcription factors, par-
ticularly NF-κB, which play a crucial role in the formation, survival,
and bone resorption activity of the osteoclasts [60,61]. The effects
of NF-κB activation are to increase osteoclastogenesis, decrease
osteoblast maturation and function, and increase chondrocyte
hypertrophy [62]. RANKL–RANK-NF-κB activation is readily
detectable in human disease samples, including inﬂammatory
arthritis, osteoporosis, osteoarthritis, PDB, multiple myeloma and
osteolytic bone metastasis [63,64]. Many clinical trails had proved
monoclonal antibody targeting RANKL (Denosumab) was more
effective at delaying skeletal-related events than zoledronic acid in
solid tumors and multiple myeloma [65–67].
P62 is an adapter protein that modulates protein–protein in-
teractions using its different types of protein–protein interaction
domains. Three of the domains; i.e., PB1, ZZ and TB, interact with
the RANKL–RANK-NF-κB pathway. The PB1 domain of P62 binds
PKCζ through a PB1–PB1 interaction, the ZZ zinc-ﬁnger domain
binds receptor interacting protein (RIP), and the TRAF6 binding
(TB) domain binds TRAF6. These three domains are relevant in the
canonical and noncanonical NF-κB activation pathways of osteo-
clastogenesis (Fig. 3).
P62 gene mutation was considered to be the main cause of
Paget's disease of bone (PDB) [25–28], which is a skeletal disorder
characterized by osteolytic lesions and overactive osteoclasts.
To date, 28 distinct P62 mutations have been reported in PDB
patients and the most commonly identiﬁed mutation leads to a
proline to leucine substitution at residue 392 (P392L) [28,68].
Dysregulated expression of P62 protein promotes osteoclastogen-
esis, bone resorption and osteolytic lesions through the NF-κBactivation pathway, leading to focal areas of aberrant and excessive
bone turnover of PDB patients [69]. In vivo, six- to-eight-week-old
P62 knockout mice showed complex signs caused by inactivation
of the osteoclasts, as well as inhibition of IKK activation and NF-κB
nuclear translocation [70]. Therefore, it is certain that P62 plays a
positive role in osteoclastogenesis through the NF-κB activation
pathway.
3.2. P62 may play an essential role in RANKL-induced autophagy
and osteoclastogenesis
Autophagy plays a changing role in osteoclastogenesis. Recently,
the roles of autophagy in the function of cartilage cells and bone
cells (primarily the osteoclasts, osteoblasts, and osteocytes) were
reviewed exhaustively [71,72]. Autophagy has dual roles, regulating
the osteoclast precursor cell pool and subsequent osteoclast for-
mation and activation. On the one hand, the activation of autophagy
promotes osteoclast formation and function. The deletion of ATG7
and ATG5 reduced the formation and resorptive capacity of osteo-
clasts in conditional knockout mice [73,74]. On the other hand, the
induction of autophagy may negatively regulate both osteoclast
formation and activity. Treatment with rapamycin (which induces
autophagy by inhibiting mTOR) has been reported to reduce the
number of osteoclasts in young rats [75] and to reduce osteoclast
formation and bone resorption in experimental mouse models of
arthritis [76]. Therefore, as a substrate of autophagy, P62 expression
was changed according to autophagy activity [77]. A recent study
investigated the correlation of P62-autophagy–osteoclastgenesis.
Using RT-PCR and Western-blot immunoﬂuorescence analyses, the
data showed that the expression of P62 was signiﬁcantly altered
during RANKL-induced osteoclast differentiation. Importantly, the
knockdown of P62 obviously attenuated RANKL-induced expression
of autophagy- and osteoclastogenesis-related genes. These in-
dicated that P62 may play essential roles in RANKL-induced au-
tophagy and osteoclastogenesis [78].
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osteoclastogenesis
In oxidative stress, reactive oxygen species (ROS) are crucial in
bone homeostasis through the stimulation of osteoclasts, the in-
hibition of osteoblasts, and the induction of osteocyte apoptosis
[79]. RANKL induces the production of long-lived ROS that are
crucial for the late stages of osteoclastogenesis and regulation of
bone resorption [80]. As previously mentioned, P62 was a novel
mediator in KEAP1/NRF2 signaling of oxidative stress [44]. A re-
cent study showed that the S349T mutation of P62 linked KEAP1/
NRF2 signaling to PDB. The S349T mutant P62 showed reducing
ability to activate NRF2 signaling in differentiating osteoclast-like
cells [81]. Therefore, NRF2 deﬁciency promoted RANKL-induced
osteoclast differentiation [82]. This may be a new mechanism for
the role of P62 in PDB [68]. On the other hand, the correlation
between oxidative stress and autophagy has long been known
[83]. As a key role in oxidative stress and autophagy crosstalk, the
phosphorylation of P62 activates the NRF2-KEAP1 pathway during
selective autophagy [84]. Interestingly, the P62 NRF2-autophagy
regulation appears to rely on dual feedback loops. First, a positive
feedback loop is the regulation of P62 expression by NRF2, which
in turn regulates NRF2 stabilization and degradation [85]. There-
fore, P62 regulates its own transcription by controlling NRF2 ac-
tivation. Second, starvation has been reported to induce ROS for-
mation, which in turn triggers autophagy [86]. It creates a negative
feedback loop whereby, under the conditions of starvation, ROS
formation stimulates autophagy, which will result in the de-
gradation of P62 and the attenuation of NRF2 activation [45]. In
short, P62-NRF2-autophagy feedback loops may play a novel role
in oxidative stress and osteoclastogenesis.4. P62 as an oncotarget for treatment
4.1. Knockdown of P62 for tumor and bone metastasis
As previously mentioned, the multi-functional domains of the
P62 adapter protein determine its role as a versatile multitasker in
signal transduction [5]. P62 plays different roles in tumorigenesis,
osteoclastogenesis, autophagy and oxidative stress. In theory,
knockdown of P62 expression would lead intricate cellular reactions.
However, the existing research showed knockdown of P62 expres-
sion was an attractive target for tumor and bone disease. The earlier
studies found that some medicines, such as chloroquine [87] and
calpain inhibitor [88], induced anti-tumor activity through P62
clearance. Later studies showed RNAi silencing of P62 signiﬁcantly
inhibited tumor growth both in vitro and in xenograft tumors model
[29–31]. A puzzling aspect of the anti-tumor mechanism is interac-
tion between P62 and autophagy. Down-regulation of P62 showed
anti-tumor activity, but it also activated autophagy, which promoted
tumor growth conversely. Nihira studied P62 inhibition on the reg-
ulation of autophagy and cell survival in P62-positive carcinoma cells.
The results showed P62-silencing dramatically suppressed cell pro-
liferation and activated autophagy. However, this autophagy is deﬁ-
cient, which was manifested as formation of mis-regulated autop-
hagosomes with multilayer membranes and an autophagic cell death
[29]. Islam showed similar results in a K-rasLA1 mice model. Using an
osmotically active polysorbitol-mediated transporter (PSMT) to
downregulate P62 by an RNAi strategy, autophagy was over-activated
and remarkably reduced the size and number of tumors by sup-
pressing proliferative cell nuclear antigen, CD 31, and VEGF levels
[30]. In short, knockdown of P62 was a promising strategy for tumor
targeted treatment.
The ability of P62 to modulate tumors and osteoclasts suggests
that it may be a feasible oncotarget for bone metastasis, especiallyfor osteolytic metastasis. First, P62 is required for the cell survival
of apoptosis-resistant bone metastatic prostate tumor (PCa) cells.
In bone metastatic lines that escape the bone marrow stromal cell
paracrine factors (BMSC-PF), induced apoptosis can upregulate
cytoprotective autophagy. In these PCa cell lines, the BMSC-PF
signaling upregulated the P62 mRNA and protein by IL-1β [89], the
siRNA knockdown of P62 was cytotoxic and the immunostaining
showed a peri-nuclear clustering of the autolysosomes. Therefore,
P62 could be exploited to target and kill these apoptosis-resistant
PCa cells in the bone [9]. Secondly, P62 is also an attractive ther-
apeutic target for multiple myeloma (MM) that is characterized by
osteolytic destruction. Knocking-down P62 in patient-derived
stromal cells signiﬁcantly decreased the PKCζ, VCAM-1, and IL-6
levels as well as decreasing the stromal cell support of MM cell
growth. Similarly, marrow stromal cells from P62-/- mice produced
much lower levels of IL-6, TNF-α, RANKL and supported MM cell
growth and osteoclast formation to a much lower extent than in
normal cells [22]. The latest study reveals that P62 aggregation is a
faithful marker of defective proteostasis, deﬁning a novel prog-
nostic and therapeutic framework for MM [90]. An exciting recent
study showed that osteolytic metastasis is hampered by impinging
on the interplay among autophagy, anoikis and ossiﬁcations. Os-
teolytic metastasis was largely prevented because of an autophagy
failure marked by P62 without Beclin-1 [91]. However, an accurate
molecular mechanism is still unclear.
4.2. P62 vaccine for tumor and bone disease treatment
The abundant studies on P62, tumors and PDB raises the pos-
sibility of a P62 vaccine for tumor and bone disease treatment. In
2013, Franco ﬁrst performed a preclinical study of a novel DNA
vaccine encoding P62 [32]. Surprisingly, the P62 vaccine showed
broad-spectrum anti-tumor and anti-metastatic activity. In-
tramuscularly or intravenously administered P62 DNA vaccine in-
duced anti-P62 antibodies and exhibited strong antitumor activity
in four models of allogeneic mouse tumors; i.e., B16 melanoma,
Lewis lung carcinoma, S37 sarcoma, and Ca755 breast carcinoma.
A P62 DNA vaccine also dramatically decreased the number or
sizes (volumes) of lung or lymphatic metastases. Then, Vladimir
analyzed the feasibility a P62 DNA vaccine as a tumor immuno-
therapy target [92]. P62 protein ﬁts the following antigen criteria:
(i) immunogenic; (ii) essential for tumors cells (to avoid its loss
through immune-editing), but dispensable for normal tissues to
reduce the risk of toxicity, and (iii) overexpressed in tumors
compared to the normal tissues. They subsequently demonstrated
that P62 DNA plasmids, when administered in a preoperative
setting, decreased and/or stabilized growth of advanced lesions in
canine mammary tumors. These studies proved the P62 vaccine
not only had good antitumor and anti-metastatic activity but also
little toxicity [32,33]. Recently, this team reported an unexpected
ﬁnding that intramuscular delivery of a P62 vaccine exerts a
powerful anti-osteoporotic activity in a mouse model of in-
ﬂammatory bone loss by combining bone-sparing and osteosyn-
thetic effects. Notably, the suppression of osteoporosis by a P62
vaccine was associated with sharp down-regulation of master in-
ﬂammatory cytokines, and up-regulation of endogenous P62
protein by bone-marrow stromal cells. However, the study failed
to detect the osteoclast activity when the P62 vaccine was ad-
ministered in vivo [34]. On the whole, the data provide a solid
rational to apply a P62 DNA vaccine as a safe, new therapeutic
treatment for tumor and bone loss diseases. Therefore, in an os-
teolytic metastasis model, which was characterized by tumor and
bone loss disease, we could hypothesis that a P62 vaccine may
exert a combined effect in osteolytic metastasis treatment.
J. Zhang et al. / Journal of Bone Oncology 5 (2016) 30–37 355. Concluding remarks
P62 is a cellular “Swiss army knife,” with its diverse cellular
functions arising from its unique functional motifs and protein–
protein interaction properties. P62 may play different roles in
different type cells or different states of cells. For example, in
tumor cells, P62 accumulation results in perturbation of gene
expression, increased genome damage and tumorigenesis [6].
However, in tumor stromal cells, P62 up-regulation is an anti-in-
ﬂammatory tumor suppressor that acts through the modulation
of metabolism [93]. At the same time, its multifunctional nature
may contribute to its complex role in osteolytic metastasis. For
example, the up-regulation of P62 can promote osteoclastogenesis
and differentiation by activating RANKL–RANK-NF-κB signaling,
thereby accelerating bone resorption. This implies that P62 may
promote osteolytic metastasis. However, as a receptor protein of
autophagy, P62 accumulated because of autophagy failure, which
hampered osteolytic metastasis. This implies that P62 may
be, contradictorily, a reducer of osteolytic metastasis. In another
example, as previously noted, the P62-NRF2-autophagy signal
feedback loop includes two contradictory types, also playing an
important role in osteoclastogenesis, and appears to be similar to
the P62-mTOR-autophagy feedback in fat metabolism [94]. As a
whole, these apparently contradictory roles showed that P62 is a
multi-domain protein that may play different roles in different
types of cells and in different microenvironments. Nevertheless,
the ability of P62 to modulate tumors and osteoclasts suggests that
it may be a feasible oncotarget for bone metastasis, especially for
osteolytic metastasis. P62 may be an attractive target for ther-
apeutic intervention if we are able to selectively modulate the
interactions of P62 with speciﬁc signaling molecules, perhaps by
using different interaction modules inherent in its structure.
Molecule targeted therapy is an important developing direction
for tumor treatments, and the key to its success is the identiﬁca-
tion of crucial molecular targets. The mechanism of osteolytic
metastasis involves different types of cells and intricate molecular
signaling. P62 is at the interface of both tumor cells and osteo-
clasts, at the juncture of different signaling pathways that are
correlated with tumorigenesis, metastasis and bone turnover.
Therefore, selective regulation of P62 expression may be a feasible
strategy for bone metastasis, especially for osteolytic metastasis.
To date, several animal studies using the P62 vaccine showed
broad-spectrum anti-tumor, anti-metastatic and anti-osteoporotic
activity. A number of human clinical trials of DNA vaccines have
been performed or are ongoing for tumors and showed encoura-
ging results [95]. Further studies should be designed to detect P62
expression in osteolytic metastasis tissues. Meanwhile, evaluating
the curative effects of down-regulating P62 expression in osteo-
lytic metastasis animal models may provide an experimental basis
for new targeted treatments.Competing interests
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